Cargando…

The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials

A clear evidence on the benefits of somatostatin analogues (SA) on liver outcome in patients affected by polycystic liver disease is still lacking. We performed a meta-analysis of RCTs and a trial sequential analysis (TSA) evaluating the effects of SA in adult patients with polycystic liver disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Garofalo, Carlo, Capuano, Ivana, Pennino, Luigi, De Gregorio, Ilaria, Riccio, Eleonora, Provenzano, Michele, Crocetto, Felice, Buonanno, Pasquale, Pandolfo, Savio Domenico, Andreucci, Michele, Pisani, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648823/
https://www.ncbi.nlm.nih.gov/pubmed/34873228
http://dx.doi.org/10.1038/s41598-021-02812-z
_version_ 1784610892170657792
author Garofalo, Carlo
Capuano, Ivana
Pennino, Luigi
De Gregorio, Ilaria
Riccio, Eleonora
Provenzano, Michele
Crocetto, Felice
Buonanno, Pasquale
Pandolfo, Savio Domenico
Andreucci, Michele
Pisani, Antonio
author_facet Garofalo, Carlo
Capuano, Ivana
Pennino, Luigi
De Gregorio, Ilaria
Riccio, Eleonora
Provenzano, Michele
Crocetto, Felice
Buonanno, Pasquale
Pandolfo, Savio Domenico
Andreucci, Michele
Pisani, Antonio
author_sort Garofalo, Carlo
collection PubMed
description A clear evidence on the benefits of somatostatin analogues (SA) on liver outcome in patients affected by polycystic liver disease is still lacking. We performed a meta-analysis of RCTs and a trial sequential analysis (TSA) evaluating the effects of SA in adult patients with polycystic liver disease on change in liver volume. As secondary outcome, we evaluated the effects on quality of life as measured by SF36-questionnaire. Six RCTs were selected with an overall sample size of 332 adult patients with polycystic liver disease (mean age: 46 years). Mean liver volume at baseline was 3289 ml in SA group and 3089 ml in placebo group. Overall, unstandardized mean difference in liver volume was − 176 ml (95%CI, − 406, 54; p < 0.133). Heterogeneity was low (I(2):0%, p < 0.992). However, we performed a moderator analysis and we found that a higher eGFR significantly correlates to a more pronounced effect of SA on liver volume reduction (p = 0.036). Cumulative Z-curve in TSA did not reach either significance and futility boundaries or required information size. Three RCTs have evaluated Quality of life parameters measured by SF36-QOL questionnaire for a total of 124 patients; no significant difference was found on the effect of SA on QOL parameters when compared with placebo. The present meta-analysis revealed a potential effect of SA on reduction of liver volume and quality of life parameters, but results did not reach a statistical significance. These data could be explained by the need of further studies, as demonstrated through TSA, to reach an adequate sample size to confirm the beneficial outcomes of SAs treatment.
format Online
Article
Text
id pubmed-8648823
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-86488232021-12-08 The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials Garofalo, Carlo Capuano, Ivana Pennino, Luigi De Gregorio, Ilaria Riccio, Eleonora Provenzano, Michele Crocetto, Felice Buonanno, Pasquale Pandolfo, Savio Domenico Andreucci, Michele Pisani, Antonio Sci Rep Article A clear evidence on the benefits of somatostatin analogues (SA) on liver outcome in patients affected by polycystic liver disease is still lacking. We performed a meta-analysis of RCTs and a trial sequential analysis (TSA) evaluating the effects of SA in adult patients with polycystic liver disease on change in liver volume. As secondary outcome, we evaluated the effects on quality of life as measured by SF36-questionnaire. Six RCTs were selected with an overall sample size of 332 adult patients with polycystic liver disease (mean age: 46 years). Mean liver volume at baseline was 3289 ml in SA group and 3089 ml in placebo group. Overall, unstandardized mean difference in liver volume was − 176 ml (95%CI, − 406, 54; p < 0.133). Heterogeneity was low (I(2):0%, p < 0.992). However, we performed a moderator analysis and we found that a higher eGFR significantly correlates to a more pronounced effect of SA on liver volume reduction (p = 0.036). Cumulative Z-curve in TSA did not reach either significance and futility boundaries or required information size. Three RCTs have evaluated Quality of life parameters measured by SF36-QOL questionnaire for a total of 124 patients; no significant difference was found on the effect of SA on QOL parameters when compared with placebo. The present meta-analysis revealed a potential effect of SA on reduction of liver volume and quality of life parameters, but results did not reach a statistical significance. These data could be explained by the need of further studies, as demonstrated through TSA, to reach an adequate sample size to confirm the beneficial outcomes of SAs treatment. Nature Publishing Group UK 2021-12-06 /pmc/articles/PMC8648823/ /pubmed/34873228 http://dx.doi.org/10.1038/s41598-021-02812-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Garofalo, Carlo
Capuano, Ivana
Pennino, Luigi
De Gregorio, Ilaria
Riccio, Eleonora
Provenzano, Michele
Crocetto, Felice
Buonanno, Pasquale
Pandolfo, Savio Domenico
Andreucci, Michele
Pisani, Antonio
The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials
title The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials
title_full The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials
title_fullStr The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials
title_full_unstemmed The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials
title_short The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials
title_sort effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648823/
https://www.ncbi.nlm.nih.gov/pubmed/34873228
http://dx.doi.org/10.1038/s41598-021-02812-z
work_keys_str_mv AT garofalocarlo theeffectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT capuanoivana theeffectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT penninoluigi theeffectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT degregorioilaria theeffectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT riccioeleonora theeffectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT provenzanomichele theeffectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT crocettofelice theeffectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT buonannopasquale theeffectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT pandolfosaviodomenico theeffectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT andreuccimichele theeffectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT pisaniantonio theeffectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT garofalocarlo effectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT capuanoivana effectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT penninoluigi effectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT degregorioilaria effectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT riccioeleonora effectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT provenzanomichele effectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT crocettofelice effectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT buonannopasquale effectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT pandolfosaviodomenico effectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT andreuccimichele effectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials
AT pisaniantonio effectsofsomatostatinanaloguesonlivervolumeandqualityoflifeinpolycysticliverdiseaseametaanalysisofrandomizedcontrolledtrials